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Adenosine Triphosphate-Sensitive Potassium Channel Kir Subunits
Implicated in Cardioprotection by Diazoxide
Matthew C. Henn, MD; M. Burhan Janjua, MD; Evelyn M. Kanter, BS; Carol M. Makepeace, BS; Richard B. Schuessler, PhD;
Colin G. Nichols, PhD; Jennifer S. Lawton, MD
Background-—ATP-sensitive potassium (KATP) channel openers provide cardioprotection in multiple models. Ion ﬂux at an
unidentiﬁed mitochondrial KATP channel has been proposed as the mechanism. The renal outer medullary kidney potassium
channel subunit, potassium inward rectifying (Kir)1.1, has been implicated as a mitochondrial channel pore-forming subunit. We
hypothesized that subunit Kir1.1 is involved in cardioprotection (maintenance of volume homeostasis and contractility) of the KATP
channel opener diazoxide (DZX) during stress (exposure to hyperkalemic cardioplegia [CPG]) at the myocyte and mitochondrial
levels.
Methods and Results-—Kir subunit inhibitor Tertiapin Q (TPN-Q) was utilized to evaluate response to stress. Mouse ventricular
mitochondrial volume was measured in the following groups: isolation buffer; 200 lmol/L of ATP; 100 lmol/L of DZX+200 lmol/L
of ATP; or 100 lmol/L of DZX+200 lmol/L of ATP+TPN-Q (500 or 100 nmol/L). Myocytes were exposed to Tyrode’s solution
(5 minutes), test solution (Tyrode’s, cardioplegia [CPG], CPG+DZX, CPG+DZX+TPN-Q, Tyrode’s+TPN-Q, or CPG+TPN-Q), N=12 for all
(10 minutes); followed by Tyrode’s (5 minutes). Volumes were compared. TPN-Q, with or without DZX, did not alter mitochondrial or
myocyte volume. Stress (CPG) resulted in myocyte swelling and reduced contractility that was prevented by DZX. TPN-Q prevented the
cardioprotection afforded by DZX (volume homeostasis and maintenance of contractility).
Conclusions-—TPN-Q inhibited myocyte cardioprotection provided by DZX during stress; however, it did not alter mitochondrial
volume. Because TPN-Q inhibits Kir1.1, Kir3.1, and Kir3.4, these data support that any of these Kir subunits could be involved in the
cardioprotection afforded by diazoxide. However, these data suggest that mitochondrial swelling by diazoxide does not involve
Kir1.1, 3.1, or 3.4. ( J Am Heart Assoc. 2015;4:e002016 doi: 10.1161/JAHA.115.002016)
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I n an isolated model of myocardial stunning, cardiacmyocytes demonstrate signiﬁcant swelling and reduced
contractility during exposure to 3 different stresses: hypo-
thermic hyperkalemic cardioplegia (CPG), hypo-osmotic
stress, or metabolic inhibition.1–3 The ATP-sensitive potas-
sium channel (KATP) opener, diazoxide (DZX), ameliorates
these stress-induced derangements in mouse, rabbit, and
human tissue.1–5 A role of KATP channels in ischemic
preconditioning, by coupling membrane conductance of K+
ions to the metabolic state of the cell, has also been well
deﬁned in multiple animal models.6–10 However, no precise
mechanism of cardioprotection has been identiﬁed.
KATP channels are formed as hetero-octamers of subunits
that include 4 potassium inward rectifying (Kir) subunits and 4
regulatory subunits from the sulfonylurea receptor family
(SUR1/2).11–13 Different combinations of Kir and SUR
isoforms exist in different tissues, each with unique properties
and function. For example, the predominant combination of
subunits found in murine ventricle is Kir6.2 and SUR2A,
whereas murine atria mainly consist of Kir6.2 and SUR1.14
Identiﬁcation of these subunits has allowed for genetic
manipulation to more speciﬁcally evaluate the mechanism
of DZX.
Using KATP subunit-knockout animal models, we have
shown that the cardioprotection afforded by DZX requires the
regulatory subunit, SUR1, but the pore-forming subunit
involved remains elusive.15,16 We have also demonstrated
that the sarcolemmal KATP channel (sKATP) is implicated in
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myocyte swelling secondary to stress, and that knockout of
the pore-forming subunit of this channel (Kir6.2) provides
resistance to myocyte swelling.2,17 However, there is evi-
dence that DZX cardioprotection does not require the sKATP
channel, leading us to propose mechanisms that may include
non-KATP channel or mitochondrial KATP channel (mKATP)
locations of action.15,16,18–21
Regulation of mitochondrial volume through a purported
mKATP channel is one of the proposed mechanisms of action
of DZX.22–24 Because no molecular composition of mKATP has
been determined, identiﬁcation of mKATP channel subunits has
to date involved indirect methods, such as pharmacological
inhibition or observed changes in mitochondrial volume
(proposed assay of mKATP activity).
24,25 Using such strategies,
the inward rectiﬁer potassium channel subunit, Kir1.1 (renal
outer medullary kidney channel; ROMK) has been implicated
as a pore-forming subunit of the mKATP channel utilizing the
nonspeciﬁc inhibitor Tertiapin Q (TPN-Q).24
The present study was conducted to assess potential roles
of Kir1.1, Kir3.1, and Kir3.4 in the cardioprotection of DZX at
the cellular and mitochondrial levels using the Kir subunit
inhibitor, TPN-Q.
Methods
All animal procedures were approved by the Animal Studies
Committee at Washington University School of Medicine, and
all animals received humane care in compliance with the
National Institute of Health’s (NIH) Guide to Care and Use of
Laboratory Animals.26
Mitochondrial Isolation
Mice (both sexes, 6 weeks to 5 months and 15 to 30 g in
weight) were anesthetized with 3% Avertin (0.3 g of 2,2,
2-tribromoethanol, 0.186 mL of 2-methyl2-butanol, and
9.814 mL of sterile water) intraperitoneally, and rapid cardi-
ectomy was performed. To isolate mitochondria, atria were
excised and discarded whereas ventricular tissue was rapidly
minced in cold buffer (in mmol/L: 10 HEPES (N-[2-hydroxy-
ethyl]1,3–5 piperazine-N-[4-butanesulfonic acid]), 1 EDTA-
potassium, 250 sucrose, adjusted to a pH of 7.1 with 20%
KOH and transferred to a 10-mL glass tube with a Teﬂon
pestle (Glas-Col Homogenizer, Terre Haute, IN), and volume
was adjusted to 7 mL with buffer. Tissue was mechanically
homogenized with a Teﬂon pestle driven by a low-speed motor
drive shaft set at 120 rpm. The homogenate was transferred
to 6 microcentrifuge tubes and centrifuged at 900g for
10 minutes at 4°C. The supernatant was combined into a
clean test tube and mixed to get a homogeneous solution that
was divided equally between 6 clean microcentrifuge tubes
and centrifuged at 5000g for 15 minutes. One pellet was
resuspended in 100 lL of buffer, and 10 lL was taken in
duplicate for the Bradford protein assay (Thermo Scientiﬁc;
Rockford, IL) to determine total protein. Each pellet was
maintained on ice and was resuspended in test media volume
to equal 0.3 lg/lL in order to standardize protein content.
Mitochondrial Volume Measurement
The volume of isolated mitochondria was measured after
suspension in test solution: (1) isolation buffer (No ATP; n=13);
(2) 200 lmol/L of ATP (n=12); (3) 200 lmol/L of ATP and
100 lmol/L of DZX (Sigma-Aldrich, St. Louis, MO) (n=12); (4)
200 lmol/L of ATP, 100 lmol/L of DZX, and 500 nmol/L of
TPN-Q (n=7); or (5) 200 lmol/L of ATP, 100 lmol/L of DZX,
and 100 nmol/L of TPN-Q (n=6). Isolation buffer (10 mmol/L
of HEPES, 200 mmol/L of mannitol, 50 mmol/L of sucrose,
1 mmol/L of EGTA; pH 7.2) was used as a control solution. ATP
has been shown to close mitochondrial KATP channels, so
200 lmol/L of ATP was used to slow the initial rate of
mitochondrial swelling (0% Mito KATP activity).
22 Conversely,
DZX activates “Mito KATP” channels, and 100 lmol/L of DZX
was added to achieve maximal activation of mitochondrial KATP
channels (100% Mito KATP activity). We were unable to
reproduce the TPN-Q dose-response relationships on mito-
chondrial volume demonstrated by other investigators using 4
TPN-Q concentrations (0.5, 10, 90, or 1000 pmol/L) despite
attempts utilizing 3 different vehicles for TPN-Q: 20% acetoni-
trile, water, and HEPES.24 In the present study, water was used
as a vehicle for TPN-Q because of its stability in themedium and
because 20% acetonitrile alone resulted in myocyte swelling
owing to its cyanide moiety.
Mitochondrial matrix volume measurements were obtained
using a light-scattering technique,27 where the absorbance, at
520 nm, of a solution of isolated mitochondria was obtained
every 14 seconds for the period of 3 minutes using UV Probe
2.33 (Shimadzu Scientiﬁc Instruments, Columbia, MD) and a
spectrophotometer (UV-1700 Spectrophotometer; Shimadzu
Scientiﬁc Instruments, Columbia, MD).
Myocyte Isolation
Ventricular myocytes were isolated from C57BL/6J mice of
either sex (age 6 weeks to 5 months and 15 to 30 g in weight),
as previously described.15 Mice were anesthetized with 2.5%
Avertin intraperitoneally. Heparin (0.1 mL) was administered
intraperitoneally. Rapid cardiectomy was performed and solu-
tion A (described below) was perfused through the aorta for
5 minutes. The heart was then perfused at 37°C for 12 to
20 minutes with solution B (described below). Ventricles were
removed, minced, and placed into solution C (described below)
and gently dispersed by glass pipette. Cells were allowed to
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centrifuge by gravity, and serial washings were performed
every 10 minutes for 15 to 20 minutes. Cells were used within
5 hours and randomized to treatment group. A typical yield of
viable myocytes was 65% to 75%.
Solution A consisted of (in mmol/L, except as noted)
116 NaCl; 5.36 KCl; 0.97 Na2HPO4; 1.47 KH2PO4; 21.10
HEPES (N-[2-hydroxyethyl] piperazine-N0-[4-butanesulfonic
acid]); 11.65 glucose; 26.50 lmol/L of phenol red (Sigma-
Aldrich); 3.72 MgCl2; 4.40 NaHCO3; essential vitamins
(1009, 10 mL; GIBCO, Grand Island, NY); and amino acids
(509, 20 mL; GIBCO). Solution B consisted of solution A plus
10 lmol/L of CaCl2; 1.2 mg/mL of collagenase (Type 2;
Worthington Biochemical Corporation, Freehold, NJ). Solution
C consisted of solution A plus 5 mg/mL of BSA (Sigma-
Aldrich); 1.25 mg/mL of taurine; and 150 lmol/L of CaCl2.
Myocytes were exposed to 37°C control TYR for 5 minutes
to obtain baseline volume. Any changes in cell volume
secondary to the isolation would be evident during this period.
Myocytes were then exposed to test solution (10 minutes)
followed by re-exposure to TYR solution (5 minutes). Test
solutions included the following groups (n=12 for each):
(1) TYR; (2) CPG; (3) CPG+100 lmol/L of DZX;
(4) CPG+100 lmol/L of DZX+TPN-Q 200 nm/L; (5) TYR+TPN-Q;
and (6) CPG+TPN-Q.
CPG consisted of (in mmol/L): NaCl 110, NaHCO3 10, KCl
16, MgCl2 16, and CaCl2 1.2 and was equilibrated with 95% O2
to 5% CO2 and titrated to the pH of 7.3 with 10% NaHCO3
solution. Diazoxide (7-chloro-3-methyl-1,2,4-benzothiadiazine-1,
1-dioxide4; Sigma-Aldrich) dose of 100 lmol/L was utilized
because it was effective in ameliorating cell swelling secondary
to stress in previous studies.1–4 A stock solution of DZX was
made by dissolving DZX in 0.1% dimethyl sulfoxide (DMSO), at
which concentration DMSO has no effect on cell volume.28
Myocyte Volume Measurement
Myocytes were used on the day of isolation and were not
cultured. Myocytes were visualized on an inverted microscope
stage (IX-51; Olympus, Tokyo, Japan), as previously
described.15 After 5 minutes, the chamber was perfused at a
rate of 3 mL/min with TYR (in mmol/L): NaCl 130, KCl 5, CaCl2
2.5, MgSO4 1.2, NaHCO3 24, Na2HPO4 1.75, and glucose 10
(buffered to a pH of 7.4 using 95% O2 to 5% CO2). After viability
was conﬁrmed, myocyte images were captured using video-
based edge detection software (IonOptix, Milton, MA) and
volume measured every 5 minutes, as previously described.5
Myocyte Contractility
Myocyte contractility was measured using a video-based edge
detection system (IonOptix). Cells were paced using a ﬁeld
stimulator (MyoPacer; IonOptix) at a voltage of 105 above
threshold at a frequency of 1 Hz with a 5-ms duration to avoid
occurrence of fusion beats. After 5 minutes of stimulation,
data were obtained from 12 to 30 consecutive beats and
averaged. Parameters of contractility included percentage
of cell shortening, maximal velocity of shortening, and
percentage of cell relengthening, as previously described.5
Contractility was measured at baseline and after 5 minutes of
re-exposure to TYR. Cells that showed less than 7% cell
shortening at baseline were excluded.
Statistical Analysis
Data were analyzed using SYSTAT 13 (Systat Software, Inc,
Point Richmond, CA). All data are presented as meanSEM
relative to baseline. A repeated-measures ANOVA was used for
sequential time-based measurements for each test solution
against its own baseline and control values. Using Fisher’s
least signiﬁcant different test, post-hoc multiple comparisons
were done between different test groups at different time
points during test solution and re-exposure periods. Probability
values <0.05 were considered signiﬁcant. A Shapiro-Wilk test
was used to test for normality. If the data failed the normality
test, a nonparametric (Friedman’s nonparametric repeated-
measures comparison) was used. Statistical analysis was
performed using SyStat 10.2 (Systat Software).
Results
Mitochondrial Matrix Volume
Isolated mitochondrial volume is represented in Figure 1.
There were no statistically signiﬁcant differences in mito-
chondrial volume between any of the groups.
Myocyte Volume
Myocyte volume over time is represented in Figure 2.
Myocytes demonstrated no signiﬁcant volume change from
baseline during exposure to TYR with or without TPN-Q.
Myocytes did demonstrate signiﬁcant swelling when exposed
to CPG (P<0.05 vs. TYR). This swelling was prevented by
addition of DZX (P<0.05 vs. CPG). The further addition of TPN-
Q prevented this beneﬁt (volume homeostasis) of DZX
(CPG+DZX+TPN-Q P<0.05 vs. CPG+DZX). As expected, the
interaction between experimental groups and time was
signiﬁcant (P<0.001).
Myocyte Contractility
Myocyte contractility is presented in Figure 3. Contractility
remained unaltered in the TYR group. Myocytes demonstrated
a signiﬁcant decline in all 3 parameters of contractility after
DOI: 10.1161/JAHA.115.002016 Journal of the American Heart Association 3
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exposure to CPG (P<0.05 vs. TYR) that was worsened by the
addition of TPN-Q. The addition of DZX to CPG prevented the
signiﬁcant reduction in contractility observed in the CPG
group. TPN-Q inhibited the protection provided by DZX.
Discussion
In previous studies, we have shown that myocyte swelling and
reduced contractility in response to stress (hyperkalemic CPG,
hypoosmotic stress, and metabolic inhibition) are ameliorated
by addition of the KATP channel opener, DZX.
1–5 Our efforts to
localize the precise mechanism of cardioprotection afforded by
DZX have implicated an involvement of the KATP channel,
SUR1,16,19 but not the Kir6.2 subunit.2 Other investigators
have provided evidence in support of the idea that Kir1.1 (the
ROMK) is a pore-forming subunit of the mKATP channel.
24 In the
current study, changes in mitochondrial and myocyte volume
were observed in the presence of ROMK blocker TPN-Q in the
presence of DZX. A dose effect on mitochondrial volume was
not detectable using TPN-Q in the presence of DZX andmultiple
doses of TPN-Q. The stability of TPN-Q in the vehicle medium
was thus evaluated in the media, in 20% acetonitrile, HEPES,
and in water. However, no signiﬁcant change in mitochondrial
volume was observed after the addition of TPN-Q, even at high
concentrations, in contrast to other investigators.24 Thus, we
conclude that TPN-Q had no effect on mitochondrial volume in
the presence of DZX, suggesting a location of action of DZX that
was distinct from the channels targeted by TPN-Q.
Myocytes demonstrated signiﬁcant swelling in response to
CPG that was prevented by the KATP channel opener, DZX,
which is consistent with previous results.2,3 Similarly, a
correlation between myocyte volume changes and contractility
changes was consistent with previous work, supporting this
myocyte model of stunning.4,5 TPN-Q prevented this beneﬁcial
Figure 1. Mitochondrial matrix volume. Isolated mouse mito-
chondria were exposed to: (1) isolation buffer (no ATP); (2)
200 lmol/L of ATP; (3) 200 lmol/L of ATP and 100 lmol/L of
DZX; (4) 200 lmol/L of ATP, 100 lmol/L of DZX, and
500 nmol/L of TPN-Q; or (5) 200 lmol/L of ATP, 100 lmol/L
of DZX, and 100 nmol/L of TPN-Q and volume measured using
light scattering (at 520 nm) for 2 minutes. Mitochondrial matrix
volume is represented as 1/percent change in absorbance
(mitochondrial matrix swelling is inversely related to absorbance
measured at 520 nm) over time. Data are represented as
meanSEM. DZX indicates diazoxide; TPN-Q, tertiapin Q.
Figure 2. TPN-Q prevents beneﬁcial maintenance of myocyte
volume during stress by DZX. Isolated myocytes were exposed to
control Tyrode’s physiologic solution (TYR) for 5 minutes (time 0
to 5), stress (CPG, CPG+DZX, CPG+DZX+TPN-Q, CPG+TPN-Q, and
TYR+TPN-Q) for 10 minutes (time 5 to 15), followed by TYR for
5 minutes (time 15 to 20). Myocyte volume was compared. Data
are represented as meanSEM. *P<0.05 vs. TYR; ΨP<0.05 vs.
CPG+DZX. CPG indicates hypothermic hyperkalemic cardioplegia;
DZX, diazoxide; TPN-Q, tertiapin Q.
Figure 3. TPN-Q prevents beneﬁcial maintenance of myocyte
contractility after stress by DZX. Isolated mouse myocytes were
exposed to control Tyrode’s physiologic solution (TYR) for 5 min-
utes (time 0 to 5), stress (CPG, CPG+DZX, CPG+DZX+TPN-Q,
CPG+TPN-Q, and TYR+TPN-Q) for 10 minutes (time 5 to 15),
followed by TYR for 5 minutes (time 15 to 20). Myocyte contractility
was compared. Data are represented as meanSEM. *P<0.05 vs.
TYR; ΨP<0.05 vs. CPG+DZX. CPG indicates hypothermic hyperka-
lemic cardioplegia; DZX, diazoxide; TPN-Q, tertiapin Q
DOI: 10.1161/JAHA.115.002016 Journal of the American Heart Association 4















 at Washington University on August 29, 2015http://jaha.ahajournals.org/Downloaded from 
effect of DZX, thus implicating TPN-Q targets—Kir1.1, Kir3.1,
or Kir3.4—in the cardioprotection of DZX at the cellular level.
Other non–Kir TPN-Q targets or undeﬁned channel subunits
sensitive to TPN-Q may play a role (GIRK1/4, KACH, and
voltage-dependent Ca2+-activated K+ channels) in cardiopro-
tection and will be the subject of future investigations.29–31
The present study further characterizes the mechanism of
cardioprotection provided by DZX. TPN-Q did not alter DZX-
induced mitochondrial swelling, but it did inhibit myocyte
cardioprotection provided by DZX during stress. Given that
TPN-Q inhibits Kir1.1-, Kir3.1-, and Kir3.4-dependent K-
channel activities, these data support that any of these
subunits (as well as undeﬁned subunits sensitive to TPN-Q)
could be involved in the cardioprotection afforded by DZX.
However, these data also suggest that mitochondrial swelling
by DZX does not involve Kir1.1, Kir3.1, or Kir3.4 and likely
results from a yet to be identiﬁed mechanism.
Future work to identify the site and mechanism of action of
KATP channel openers will involve indirect methods until
genetic identiﬁcation is accomplished.
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